

Yasodha Natkunam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7092861/publications.pdf>

Version: 2024-02-01

265
papers

12,614
citations

34076

52
h-index

30894

102
g-index

276
all docs

276
docs citations

276
times ranked

14811
citing authors

#	ARTICLE	IF	CITATIONS
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	3.3	1,211
2	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> , 2022, 36, 1720-1748.	3.3	1,023
3	Multiplexed ion beam imaging of human breast tumors. <i>Nature Medicine</i> , 2014, 20, 436-442.	15.2	881
4	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Journal of Clinical Oncology</i> , 2016, 34, 2690-2697.	0.8	634
5	Characterization of Variant Patterns of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Immunohistologic and Clinical Correlation. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1346-1356.	2.1	311
6	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1419-1431.	15.2	273
7	Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2001, 98, 945-951.	0.6	272
8	Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. <i>Cell</i> , 2022, 185, 1025-1040.e14.	13.5	243
9	Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. <i>Blood</i> , 2013, 122, 981-987.	0.6	225
10	Expression of CD163 (Hemoglobin Scavenger Receptor) in Normal Tissues, Lymphomas, Carcinomas, and Sarcomas Is Largely Restricted to the Monocyte/Macrophage Lineage. <i>American Journal of Surgical Pathology</i> , 2005, 29, 617-624.	2.1	195
11	Software Tools for High-Throughput Analysis and Archiving of Immunohistochemistry Staining Data Obtained with Tissue Microarrays. <i>American Journal of Pathology</i> , 2002, 161, 1557-1565.	1.9	194
12	Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. <i>Blood</i> , 2003, 101, 4285-4289.	0.6	191
13	Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. <i>Blood</i> , 2011, 118, 1350-1358.	0.6	175
14	Analysis of MUM1/IRF4 Protein Expression Using Tissue Microarrays and Immunohistochemistry. <i>Modern Pathology</i> , 2001, 14, 686-694.	2.9	167
15	LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. <i>Journal of Clinical Oncology</i> , 2008, 26, 447-454.	0.8	159
16	Unifying mechanism for different fibrotic diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4757-4762.	3.3	155
17	Atypical Cellular Disorders. <i>Hematology American Society of Hematology Education Program</i> , 2004, 2004, 283-296.	0.9	154
18	Natural Killer/Natural Killer-Like T-Cell Lymphoma, CD56+, Presenting in the Skin: An Increasingly Recognized Entity With an Aggressive Course. <i>Journal of Clinical Oncology</i> , 2001, 19, 2179-2188.	0.8	153

#	ARTICLE	IF	CITATIONS
19	Classical Hodgkin Lymphoma with Reduced \hat{I}^2 M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. <i>Cancer Immunology Research</i> , 2016, 4, 910-916.	1.6	146
20	The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. <i>Blood</i> , 2007, 109, 1636-1642.	0.6	139
21	Embryonic Stem Cellâ€‘Derived Endothelial Cells Engraft Into the Ischemic Hindlimb and Restore Perfusion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 984-991.	1.1	126
22	MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. <i>Clinical Cancer Research</i> , 2011, 17, 4125-4135.	3.2	126
23	Clinicopathologic and Molecular Features of 122 Brazilian Cases of Nodal and Extranodal NK/T-Cell Lymphoma, Nasal Type, With EBV Subtyping Analysis. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1195-1203.	2.1	119
24	PTP1B is a negative regulator of interleukin 4â€‘induced STAT6 signaling. <i>Blood</i> , 2008, 112, 4098-4108.	0.6	118
25	Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. <i>Blood</i> , 2005, 105, 3979-3986.	0.6	111
26	Aggressive Cutaneous NK and NK-like T-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 1999, 23, 571-581.	2.1	107
27	Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. <i>Nature Medicine</i> , 2009, 15, 566-571.	15.2	105
28	Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. <i>Human Pathology</i> , 2018, 71, 91-99.	1.1	102
29	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. <i>Cancer Cell</i> , 2021, 39, 1422-1437.e10.	7.7	102
30	Cyclin D3 coordinates the cell cycle during differentiation to regulate erythrocyte size and number. <i>Genes and Development</i> , 2012, 26, 2075-2087.	2.7	100
31	The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. <i>Haematologica</i> , 2010, 95, 432-439.	1.7	99
32	Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyteâ€‘Predominant Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 912-918.	0.8	96
33	Oncogenic Regulators and Substrates of the Anaphase Promoting Complex/Cyclosome Are Frequently Overexpressed in Malignant Tumors. <i>American Journal of Pathology</i> , 2007, 170, 1793-1805.	1.9	92
34	Expression of the B-Cell Proliferation Marker MUM1 by Melanocytic Lesions and Comparison with S100, gp100 (HMB45), and MelanA. <i>Modern Pathology</i> , 2003, 16, 802-810.	2.9	91
35	Immunohistochemical Characterization of Nasal-Type Extranodal NK/T-Cell Lymphoma Using a Tissue Microarray. <i>American Journal of Clinical Pathology</i> , 2008, 130, 343-351.	0.4	89
36	Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. <i>Laboratory Investigation</i> , 2008, 88, 38-47.	1.7	87

#	ARTICLE	IF	CITATIONS
37	Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?. <i>Blood</i> , 2018, 132, 1871-1878.	0.6	85
38	EBV-Positive B-Cell Proliferations of Varied Malignant Potential. <i>American Journal of Clinical Pathology</i> , 2017, 147, 129-152.	0.4	84
39	CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. <i>Blood</i> , 2013, 122, 1233-1242.	0.6	82
40	The Stanford Tissue Microarray Database. <i>Nucleic Acids Research</i> , 2007, 36, D871-D877.	6.5	80
41	Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13069-13074.	3.3	79
42	Microvessel Density and Expression of Vascular Endothelial Growth Factor and Its Receptors in Diffuse Large B-Cell Lymphoma Subtypes. <i>American Journal of Pathology</i> , 2007, 170, 1362-1369.	1.9	76
43	Expression Profiles of MYC Protein and MYC Gene Rearrangement in Lymphomas. <i>American Journal of Surgical Pathology</i> , 2015, 39, 294-303.	2.1	76
44	Oral and Extraoral Plasmablastic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2010, 134, 710-719.	0.4	74
45	HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms. <i>American Journal of Clinical Pathology</i> , 2017, 147, 171-187.	0.4	74
46	TdT+ T-lymphoblastic Populations Are Increased in Castleman Disease, in Castleman Disease in Association With Follicular Dendritic Cell Tumors, and in Angioimmunoblastic T-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1619-1628.	2.1	73
47	Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. <i>Nature Communications</i> , 2014, 5, 3904.	5.8	73
48	PD-1 Expression in T-cell Lymphomas and Reactive Lymphoid Entities: Potential Overlap in Staining Patterns Between Lymphoma and Viral Lymphadenitis. <i>American Journal of Surgical Pathology</i> , 2010, 34, 178-189.	2.1	71
49	The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. <i>British Journal of Haematology</i> , 2005, 128, 333-342.	1.2	69
50	Indolent T-Lymphoblastic Proliferation (iT-LBP). <i>Advances in Anatomic Pathology</i> , 2013, 20, 137-140.	2.4	65
51	Immunoblot Analysis of CD34 Expression in Histologically Diverse Neoplasms. <i>American Journal of Pathology</i> , 2000, 156, 21-27.	1.9	64
52	Immunoarchitectural Patterns in Nodal Marginal Zone B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2009, 132, 39-49.	0.4	60
53	Utility of Syndecan-1 (CD138) Expression in the Diagnosis of Undifferentiated Malignant Neoplasms. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2005, 13, 304-310.	0.6	55
54	CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas. <i>American Journal of Pathology</i> , 2012, 181, 795-803.	1.9	52

#	ARTICLE	IF	CITATIONS
55	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR ⁺ refractory large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2321-2325.	0.6	51
56	Utility of Paraffin Section Immunohistochemistry for C-KIT (CD117) in the Differential Diagnosis of Systemic Mast Cell Disease Involving the Bone Marrow. <i>American Journal of Surgical Pathology</i> , 2000, 24, 81.	2.1	49
57	The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases. <i>Modern Pathology</i> , 2012, 25, 661-674.	2.9	48
58	Apoptosis Stimulating Protein of p53 (ASPP2) Expression Differs in Diffuse Large B-cell and Follicular Center Lymphoma: Correlation with Clinical Outcome. <i>Leukemia and Lymphoma</i> , 2002, 43, 2309-2317.	0.6	47
59	Nuclear signaling by interleukin-6. <i>Current Opinion in Immunology</i> , 1993, 5, 124-128.	2.4	45
60	Blastic/Blastoid Transformation of Follicular Lymphoma. <i>American Journal of Surgical Pathology</i> , 2000, 24, 525-534.	2.1	45
61	Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases. <i>Journal of Cutaneous Pathology</i> , 2000, 27, 392-399.	0.7	45
62	Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. <i>Journal of Cutaneous Pathology</i> , 2005, 32, 227-234.	0.7	45
63	EBV Can Protect Latently Infected B Cell Lymphomas from Death Receptor-Induced Apoptosis. <i>Journal of Immunology</i> , 2006, 177, 3283-3293.	0.4	45
64	Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. <i>Blood</i> , 2007, 109, 298-305.	0.6	45
65	Epstein-Barr virus-positive follicular lymphoma. <i>Modern Pathology</i> , 2017, 30, 519-529.	2.9	44
66	Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies. <i>Blood</i> , 2018, 132, 490-490.	0.6	43
67	Loss of CD19 expression in B-cell neoplasms. <i>Histopathology</i> , 2006, 48, 239-246.	1.6	42
68	Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). <i>Leukemia and Lymphoma</i> , 2014, 55, 768-772.	0.6	42
69	Immunoarchitectural Patterns in Follicular Lymphoma: Efficacy of HGAL and LMO2 in the Detection of the Interfollicular and Diffuse Components. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1266-1276.	2.1	40
70	Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis. <i>Human Pathology</i> , 2010, 41, 1726-1734.	1.1	40
71	IgG4-Related Systemic Sclerosing Disease of the Ocular Adnexa. <i>American Journal of Clinical Pathology</i> , 2012, 137, 699-711.	0.4	40
72	Transmembrane adaptor molecules: a new category of lymphoid-cell markers. <i>Blood</i> , 2006, 107, 213-221.	0.6	39

#	ARTICLE	IF	CITATIONS
73	Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. <i>Modern Pathology</i> , 2010, 23, 420-433.	2.9	39
74	Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 119, 5478-5491.	0.6	39
75	<i>l1</i> <i>scp</i> LITAF <i>/scp</i> <i>l1</i> , a <i>scp</i> BCL <i>/scp</i> 6 target gene, regulates autophagy in mature Bâ€cell lymphomas. <i>British Journal of Haematology</i> , 2013, 162, 621-630.	1.2	39
76	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017, 102, 1413-1423.	1.7	39
77	Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (Râ€CHOP). <i>British Journal of Haematology</i> , 2010, 148, 235-244.	1.2	38
78	B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency. <i>American Journal of Clinical Pathology</i> , 2017, 147, 153-170.	0.4	38
79	TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. <i>Modern Pathology</i> , 2005, 18, 1641-1648.	2.9	37
80	Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. <i>Nature Communications</i> , 2013, 4, 1338.	5.8	37
81	Expression of the Activating Receptor, NKp46 (CD335), in Human Natural Killer and T-Cell Neoplasia. <i>American Journal of Clinical Pathology</i> , 2013, 140, 853-866.	0.4	36
82	Immunoarchitectural patterns of progressive transformation of germinal centers with and without nodular lymphocyte-predominant Hodgkin lymphoma. <i>Human Pathology</i> , 2015, 46, 1655-1661.	1.1	36
83	Selective Immunophenotyping for Diagnosis of B-cell Neoplasms. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 116-131.	0.6	35
84	Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma. <i>Human Pathology</i> , 2014, 45, 1730-1736.	1.1	34
85	Technical Considerations. , 0, , 209-213.		34
86	The Transcription Factor LMO2 Is a Robust Marker of Vascular Endothelium and Vascular Neoplasms and Selected Other Entities. <i>American Journal of Clinical Pathology</i> , 2009, 131, 264-278.	0.4	33
87	The Usefulness of Immunohistochemistry in the Diagnosis of Follicular Lymphoma in Bone Marrow Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 2002, 117, 636-643.	0.4	32
88	The utility of PAX5 immunohistochemistry in the diagnosis of undifferentiated malignant neoplasms. <i>Modern Pathology</i> , 2007, 20, 871-877.	2.9	32
89	Lmo2 expression defines tumor cell identity during Tâ€cell leukemogenesis. <i>EMBO Journal</i> , 2018, 37, .	3.5	32
90	Low Stage Follicular Lymphoma: Biologic and Clinical Characterization According to Nodal or Extranodal Primary Origin. <i>American Journal of Surgical Pathology</i> , 2009, 33, 591-598.	2.1	31

#	ARTICLE	IF	CITATIONS
91	CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. <i>Human Pathology</i> , 2010, 41, 271-280.	1.1	31
92	Molecular and genomic aberrations in <i>Chlamydomypha psittaci</i> negative ocular adnexal marginal zone lymphomas. <i>American Journal of Hematology</i> , 2013, 88, 730-735.	2.0	31
93	Expression pattern of FCRL (FREB, FcRX) in normal and neoplastic human B cells. <i>British Journal of Haematology</i> , 2004, 127, 335-343.	1.2	30
94	The Biology of the Germinal Center. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 210-215.	0.9	30
95	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. <i>Blood</i> , 2020, 135, 2365-2374.	0.6	30
96	Extracellular Signal-Regulated Kinase Positively Regulates the Oncogenic Activity of MCT-1 in Diffuse Large B-Cell Lymphoma. <i>Cancer Research</i> , 2009, 69, 7835-7843.	0.4	28
97	CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering. <i>Blood</i> , 2020, 136, 53-54.	0.6	28
98	Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1298-1304.	2.1	27
99	Large atypical cells of lymphomatoid papulosis are CD56-negative: a study of 18 cases. <i>Journal of Cutaneous Pathology</i> , 2002, 29, 88-92.	0.7	26
100	The Efficacy of HGAL and LMO2 in the Separation of Lymphomas Derived From Small B Cells in Nodal and Extranodal Sites, Including the Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2011, 135, 697-708.	0.4	26
101	<i>LMO2</i> and <i>BCL6</i> are associated with improved survival in primary central nervous system lymphoma. <i>British Journal of Haematology</i> , 2014, 165, 640-648.	1.2	26
102	An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. <i>Human Pathology</i> , 2016, 48, 9-17.	1.1	25
103	Intracellular signalling molecules as immunohistochemical markers of normal and neoplastic human leucocytes in routine biopsy samples. <i>British Journal of Haematology</i> , 2004, 124, 519-533.	1.2	23
104	C-C Chemokine Receptor 1 Expression in Human Hematolymphoid Neoplasia. <i>American Journal of Clinical Pathology</i> , 2010, 133, 473-483.	0.4	23
105	Aggressive Natural Killer-Like T-Cell Malignancy With Leukemic Presentation Following Solid Organ Transplantation. <i>American Journal of Clinical Pathology</i> , 1999, 111, 663-671.	0.4	21
106	CD10 expression in peripheral T-cell lymphomas complicated by a proliferation of large B-cells. <i>Modern Pathology</i> , 2006, 19, 337-343.	2.9	21
107	Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. <i>British Journal of Haematology</i> , 2008, 141, 69-72.	1.2	21
108	Kappa and lambda light chain mRNA in situ hybridization compared to flow cytometry and immunohistochemistry in B cell lymphomas. <i>Diagnostic Pathology</i> , 2014, 9, 144.	0.9	21

#	ARTICLE	IF	CITATIONS
109	T- and NK-Cell Lymphomas and Systemic Lymphoproliferative Disorders and the Immunodeficiency Setting. <i>American Journal of Clinical Pathology</i> , 2017, 147, 188-203.	0.4	21
110	Follicular Dendritic Cell Immunohistochemical Markers in Angioimmunoblastic T-Cell Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2005, 13, 297-303.	0.6	20
111	Cytologic diagnosis of Burkitt lymphoma. <i>Cancer</i> , 2005, 105, 310-318.	2.0	20
112	Low CD27 Expression in Plasma Cell Dyscrasias Correlates With High-Risk Disease. <i>American Journal of Clinical Pathology</i> , 2006, 126, 545-551.	0.4	20
113	Integration of Genomic Medicine into Pathology Residency Training. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 141-148.	1.2	20
114	Prognostic immunohistologic markers in human tumors: why are so few used in clinical practice?. <i>Laboratory Investigation</i> , 2006, 86, 742-747.	1.7	19
115	Microtubule-associated Protein-2 is a Sensitive Marker of Primary and Metastatic Neuroblastoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1695-1704.	2.1	19
116	Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics. <i>Cancers</i> , 2021, 13, 3021.	1.7	19
117	Modified Cyclophosphamide, Hydroxydaunorubicin, Vincristine, and Prednisone Therapy for Posttransplantation Lymphoproliferative Disease in Pediatric Patients Undergoing Solid Organ Transplantation. <i>The American Journal of Pediatric Hematology/oncology</i> , 2001, 23, 452-455.	1.3	18
118	A Novel Method for Making "Tissue" Microarrays From Small Numbers of Suspension Cells. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2005, 13, 80-84.	0.6	18
119	Defining the elusive boundaries of chronic active Epstein-Barr virus infection. <i>Haematologica</i> , 2018, 103, 924-927.	1.7	18
120	Large B-Cell Lymphomas Poor in B Cells and Rich in PD-1+ T Cells Can Mimic T-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2014, 142, 150-156.	0.4	17
121	Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF- κ B pathway. <i>International Journal of Cancer</i> , 2015, 136, 2341-2351.	2.3	17
122	Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 239-248.	0.6	17
123	Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms. <i>Haematologica</i> , 2007, 92, 176-183.	1.7	16
124	Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1830-1836.	0.6	16
125	Primary/Congenital Immunodeficiency. <i>American Journal of Clinical Pathology</i> , 2017, 147, 204-216.	0.4	16
126	Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina. <i>Annals of Diagnostic Pathology</i> , 2013, 17, 250-255.	0.6	15

#	ARTICLE	IF	CITATIONS
127	Myeloid Cell Nuclear Differentiation Antigen (MND) Expression Distinguishes Extramedullary Presentations of Myeloid Leukemia From Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>American Journal of Surgical Pathology</i> , 2016, 40, 502-509.	2.1	15
128	High frequency of CD74 expression in lymphomas: implications for targeted therapy using a novel anti-CD74 drug conjugate. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 12-24.	1.3	15
129	Extranodal NK/T-Cell Lymphomas: The Role of Natural Killer Cells and EBV in Lymphomagenesis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1501.	1.8	15
130	Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 289-295.	0.7	14
131	Characterization of c-Maf Transcription Factor in Normal and Neoplastic Hematolymphoid Tissue and Its Relevance in Plasma Cell Neoplasia. <i>American Journal of Clinical Pathology</i> , 2009, 132, 361-371.	0.4	14
132	Follicular lymphoma in young adults: a clinicopathological and molecular study of 200 patients. <i>Modern Pathology</i> , 2013, 26, 1183-1196.	2.9	14
133	Expression of the transcription factor ZBTB46 distinguishes human histiocytic disorders of classical dendritic cell origin. <i>Modern Pathology</i> , 2018, 31, 1479-1486.	2.9	14
134	Epstein-Barr virus strain type and latent membrane protein 1 gene deletions in lymphomas in patients with rheumatic diseases. <i>Arthritis and Rheumatism</i> , 1997, 40, 1152-1156.	6.7	13
135	Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countries. <i>Blood Advances</i> , 2021, 5, 2447-2455.	2.5	13
136	Variable Expression of B-cell Transcription Factors in Reactive Immunoblastic Proliferations. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1655-1663.	2.1	12
137	A single-institution retrospective analysis of outcomes for stage II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 604-608.	0.6	12
138	Is Merkel Cell Carcinoma of Lymph Node Actually Metastatic Cutaneous Merkel Cell Carcinoma?. <i>American Journal of Clinical Pathology</i> , 2020, 154, 369-380.	0.4	12
139	Immunophenotypic and Genotypic Characterization of Progression in Follicular Lymphomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2004, 12, 97-104.	0.6	11
140	DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set. <i>Scientific Data</i> , 2021, 8, 135.	2.4	11
141	Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy. <i>Blood</i> , 2018, 132, 4656-4656.	0.6	11
142	The spectrum of lymphoblastic, nodal and extranodal T-cell lymphomas: characteristic features and diagnostic dilemmas. <i>Human Pathology</i> , 2013, 44, 451-471.	1.1	10
143	CD137 Ligand Is Expressed in Primary and Secondary Lymphoid Follicles and in B-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 250-258.	2.1	10
144	Immunohistochemical Profile of MYC Protein in Pediatric Small Round Blue Cell Tumors. <i>Pediatric and Developmental Pathology</i> , 2017, 20, 213-223.	0.5	10

#	ARTICLE	IF	CITATIONS
145	Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era. International Journal of Radiation Oncology Biology Physics, 2015, 92, 67-75.	0.4	9
146	Natural Killer Cell Precursor Acute Lymphoma/Leukemia Presenting in an Infant. Archives of Pathology and Laboratory Medicine, 2001, 125, 413-418.	1.2	9
147	Expression of LMO2 Is Associated With t(14;18)/IGH-BCL2 Fusion but Not BCL6 Translocations in Diffuse Large B-Cell Lymphoma. American Journal of Clinical Pathology, 2010, 134, 278-281.	0.4	8
148	LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype. Histopathology, 2014, 64, 226-233.	1.6	8
149	Use of CD137 ligand expression in the detection of small B-cell lymphomas involving the bone marrow. Human Pathology, 2014, 45, 1024-1030.	1.1	8
150	Large B-cell lymphoma with T-cell-rich background and nodules lacking follicular dendritic cell meshworks: description of an insufficiently recognized variant. Human Pathology, 2015, 46, 74-83.	1.1	8
151	Myeloid Cell Nuclear Differentiation Antigen (MNDA) Positivity in Primary Follicles: Potential Pitfall in the Differential Diagnosis With Marginal Zone Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 384-388.	0.6	8
152	Role of FNA with core biopsy or cell block in patients with nodular lymphocyte-predominant Hodgkin lymphoma. Cancer Cytopathology, 2020, 128, 570-579.	1.4	8
153	CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center. Archives of Pathology and Laboratory Medicine, 2021, 145, 753-758.	1.2	8
154	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. Blood Cancer Discovery, 2022, 3, 154-169.	2.6	8
155	KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas. American Journal of Clinical Pathology, 2017, 148, 465-476.	0.4	7
156	Immunohistochemistry for PAX7 is a useful confirmatory marker for Ewing sarcoma in decalcified bone marrow core biopsy specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 765-769.	1.4	7
157	Survival in Follicular Lymphoma: The Stanford Experience, 1960-2003. Blood, 2007, 110, 3428-3428.	0.6	7
158	Isolated Follicles Enriched for Centroblasts and Lacking t(14;18)/BCL2 in Lymphoid Tissue: Diagnostic and Clinical Implications. PLoS ONE, 2016, 11, e0151735.	1.1	7
159	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. International Journal of Molecular Epidemiology and Genetics, 2011, 2, 245-52.	0.4	7
160	Usefulness of HGAL and LMO2 Immunohistochemistry in the Identification of Follicular Lymphomas of the Non-Gastric Gastrointestinal Tract. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 200-204.	0.6	6
161	Indolent T-lymphoblastic proliferation: a name with specific meaning. Human Pathology, 2015, 46, 1785-1786.	1.1	6
162	Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 749-757.	1.4	6

#	ARTICLE	IF	CITATIONS
163	Building Tissue Microarrays from Suspension Cells. <i>Methods in Molecular Biology</i> , 2010, 664, 93-101.	0.4	6
164	The Number of CD25+ Tumor-Infiltrating Cells May Predict Clinical Response to Rituximab in Follicular Lymphoma Patients.. <i>Blood</i> , 2004, 104, 748-748.	0.6	6
165	Durable Remission in Recurrent T-Cell Rich B-Cell Lymphoma with the Anti-CD20 Antibody Rituximab. <i>Clinical Lymphoma and Myeloma</i> , 2001, 2, 185-187.	2.1	5
166	The contribution of HGAL/GCET2 in immunohistological algorithms: a comparative study in 424 cases of nodal diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2012, 25, 1439-1445.	2.9	5
167	LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. <i>Leukemia and Lymphoma</i> , 2012, 53, 1105-1112.	0.6	5
168	Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 10-16.	0.6	5
169	Tissue Microarrays from Bone Marrow Aspirates for High-Throughput Assessment of Immunohistologic Markers in Pediatric Acute Leukemia. <i>Pediatric and Developmental Pathology</i> , 2008, 11, 283-290.	0.5	4
170	Lack of Utility of CD20 Immunohistochemistry in Staging Bone Marrow Biopsies for Diffuse Large B-cell Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009, 17, 93-95.	0.6	4
171	Aggressive EBV-associated Lymphoproliferative Disorder. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2012, 20, 325-330.	0.6	4
172	FHIT, EGFR, and MSH2. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 275-283.	0.6	4
173	Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26-year experience from an academic medical center in Brazil. <i>Diagnostic Pathology</i> , 2019, 14, 115.	0.9	4
174	KLF1/EKLF expression in acute leukemia is correlated with chromosomal abnormalities. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 83, 102434.	0.6	4
175	Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation. <i>Leukemia and Lymphoma</i> , 2021, 62, 2864-2872.	0.6	4
176	Global Cytopathology-Hematopathology Practice Trends. <i>American Journal of Clinical Pathology</i> , 2022, 157, 196-201.	0.4	4
177	The Biology of the Germinal Center. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 210-215.	0.9	4
178	Elevated Axicabtagene Ciloleuce (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 576-576.	0.6	4
179	An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 655-655.	0.6	4
180	International Standardized Approach to Molecular and Flow Cytometric Residual Disease Monitoring in CLL. <i>Blood</i> , 2004, 104, 15-15.	0.6	4

#	ARTICLE	IF	CITATIONS
181	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Blood</i> , 2015, 126, 176-176.	0.6	4
182	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 741-741.	0.6	4
183	HGAL Protein Expression Persists in Disorders of Germinal Center Dissolution. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2011, 19, 266-272.	0.6	3
184	FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the spectrum of T-cell lymphomas with regulatory phenotype. <i>Human Pathology</i> , 2018, 80, 138-144.	1.1	3
185	CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 28-29.	0.6	3
186	TNFRSF6 (Fas Antigen) Mutations in Patients with Sinus Histiocytosis with Massive Lymphadenopathy (Rosai-Dorfman Disease).. <i>Blood</i> , 2004, 104, 2389-2389.	0.6	3
187	Prognostic Significance of VEGF, VEGF Receptors, and Microvessel Density in Diffuse Large B Cell Lymphoma Treated with Anthracycline-Based Chemotherapy.. <i>Blood</i> , 2007, 110, 53-53.	0.6	3
188	Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience. <i>Blood</i> , 2011, 118, 2686-2686.	0.6	3
189	Diagnostic Impact of Next-Generation Sequencing Panels for Lymphoproliferative Neoplasms on Small-Volume Biopsies. <i>American Journal of Clinical Pathology</i> , 2022, 158, 345-361.	0.4	3
190	Bringing Pathobiology into Focus. <i>Laboratory Investigation</i> , 2006, 86, 632-632.	1.7	2
191	LMO2 protein expression predicts survival in patients with rheumatoid arthritis and diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1146-1149.	0.6	2
192	Extracavity primary effusion lymphoma presenting in a lymph node without lymphomatous effusions. <i>Human Pathology: Case Reports</i> , 2015, 2, 36-41.	0.2	2
193	Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies. <i>Human Pathology</i> , 2018, 82, 39-45.	1.1	2
194	Elusive sentinels at the Hodgkin checkpoint. <i>Blood</i> , 2020, 136, 2841-2842.	0.6	2
195	HGAL inhibits lymphoma dissemination by interacting with multiple Cytoskeletal proteins. <i>Blood Advances</i> , 2021, 5, 5072-5085.	2.5	2
196	Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage. <i>Blood</i> , 2020, 136, 30-31.	0.6	2
197	LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras.. <i>Blood</i> , 2007, 110, 52-52.	0.6	2
198	Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions.. <i>Blood</i> , 2009, 114, 622-622.	0.6	2

#	ARTICLE	IF	CITATIONS
199	High Accuracy, Low-Cost Transcriptional Diagnostic to Transform Lymphoma Care in Low- and Middle-Income Countries. <i>Blood</i> , 2019, 134, 409-409.	0.6	2
200	Human Germinal Center-associated Lymphoma (HGAL) Is a Reliable Marker of Normal and Neoplastic Follicular Helper T Cells Including Angioimmunoblastic T-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2021, Publish Ahead of Print, .	2.1	2
201	Diagnosis of NK and cytotoxic T-cell disorders: a review. <i>Diagnostic Histopathology</i> , 2018, 24, 257-266.	0.2	1
202	Additional considerations related to the elusive boundaries of EBV-associated T/NK-cell lymphoproliferative disorders. <i>Haematologica</i> , 2019, 104, e125-e126.	1.7	1
203	Stage II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1840-1849.	0.6	1
204	Evaluation of the Bone Marrow After Therapy. , 2011, , 918-938.		1
205	HGAL-a Germinal Center Specific Protein, Enhances B-Cell Receptor Signaling by Activation of Syk, Leading to Follicular Lymphoproliferation. <i>Blood</i> , 2011, 118, 584-584.	0.6	1
206	Tissue Microarrays from Bone Marrow Aspirates for High Throughput Assessment of Immunohistologic Markers in Pediatric Acute Leukemia. <i>Pediatric and Developmental Pathology</i> , 2006, preprint, 1.	0.5	1
207	Prognostic significance of CD15 expression in classical Hodgkin lymphoma (cHL): The Stanford University experience.. <i>Journal of Clinical Oncology</i> , 2010, 28, e18521-e18521.	0.8	1
208	In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In <i>Mycosis Fungoides</i> : Analysis of Phase I/II Study. <i>Blood</i> , 2010, 116, 286-286.	0.6	1
209	Processing of the Lymph Node Biopsy Specimen. , 2011, , 3-13.		1
210	Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7606-7606.	0.8	1
211	Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis. <i>Blood</i> , 2021, 138, 709-709.	0.6	1
212	Chronic Myelogenous Leukemia Presenting as Extramedullary Lymphoid Blast Crisis. , 2002, 7, 117-123.		0
213	Chronic Myelogenous Leukemia Presenting as Extramedullary Lymphoid Blast Crisis. , 2002, 7, 117-123.		0
214	Acute Leukemia. , 0, , 70-89.		0
215	Large Granular Lymphocyte Leukemia. , 0, , 165-167.		0
216	Immunohistochemical Profiling of Lymphoma. , 2010, , 21-44.		0

#	ARTICLE	IF	CITATIONS
217	T-cell lymphomas: a tale of heterogeneity masking clarity. <i>Leukemia and Lymphoma</i> , 2011, 52, 1-2.	0.6	0
218	Hodgkin Lymphoma and the Microenvironment. , 2014, , 1701-1712.		0
219	Synchronous immunophenotypically and clonally distinct follicular lymphoma and marginal zone lymphoma with massive amyloid deposition. <i>Human Pathology: Case Reports</i> , 2016, 5, 10-17.	0.2	0
220	Breast implant-associated anaplastic large cell lymphoma in the post-mastectomy setting: Clinical and therapeutic implications. <i>Human Pathology: Case Reports</i> , 2019, 18, 200340.	0.2	0
221	Novel IRF8 and PD-L1 molecular aberrations in systemic EBV-positive T-cell lymphoma of childhood. <i>Human Pathology: Case Reports</i> , 2020, 19, 200356.	0.2	0
222	FOXes at play in the lymphoma landscape. <i>Leukemia and Lymphoma</i> , 2021, 62, 5-7.	0.6	0
223	On the Shoulders of a Giant: Contributions of Thomas Grogan, MD to Hematopathology. <i>Hemato</i> , 2021, 2, 103-115.	0.2	0
224	Classic Hodgkin lymphoma in Guatemalan children of age less than six years: analysis of immune regulatory pathways and the tumor microenvironment. <i>Leukemia and Lymphoma</i> , 2021, 62, 1609-1618.	0.6	0
225	Increased double-negative \hat{I}^2+ T-cells reveal adult-onset autoimmune lymphoproliferative syndrome in a patient with IgG4-related disease. <i>Haematologica</i> , 2021, , .	1.7	0
226	Expression of the Human Germinal Center-Associated Lymphoma (HGAL) Protein, a New Marker of Germinal Center B Cell Derivation.. <i>Blood</i> , 2004, 104, 2265-2265.	0.6	0
227	Expression of the Human Germinal Center Associated Lymphoma (HGAL) Protein Identifies a Subset of Classical Hodgkin Lymphoma of Germinal Center Derivation and Improved Outcome.. <i>Blood</i> , 2005, 106, 23-23.	0.6	0
228	RNA-Binding Protein VICKZ Is Expressed in a Germinal Center Associated Pattern among Lymphoma Subtypes.. <i>Blood</i> , 2005, 106, 1909-1909.	0.6	0
229	The Oncoprotein LMO2 Is Expressed in a Germinal Center B-Cell-Associated Pattern and Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2006, 108, 810-810.	0.6	0
230	Biological and clinical effects of single agent treatment with atorvastatin in patients with non-Hodgkinâ€™s lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 8529-8529.	0.8	0
231	Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960â€™2003. <i>Journal of Clinical Oncology</i> , 2008, 26, 8535-8535.	0.8	0
232	LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study. <i>Blood</i> , 2008, 112, 3769-3769.	0.6	0
233	Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). <i>Journal of Clinical Oncology</i> , 2009, 27, 8581-8581.	0.8	0
234	Oral and extraoral plasmablastic lymphoma: Similarities and differences in clinicopathological characteristics.. <i>Journal of Clinical Oncology</i> , 2010, 28, e18539-e18539.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies. Blood, 2010, 116, 3134-3134.	0.6	0
236	Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. Blood, 2010, 116, 2006-2006.	0.6	0
237	STAT3, Constitutively Activated In ABC-Like DLBCL, Regulates Expression of the Prognostic Factor Cyclin D2. Blood, 2010, 116, 705-705.	0.6	0
238	Identification of LMO2 Transcriptome and Interactome in Diffuse Large B-Cell Lymphoma by Integrated Experimental and Computational Approach. Blood, 2011, 118, 438-438.	0.6	0
239	Immature T-Cell Populations in Lymph Nodes of Castleman Disease and Angioimmunoblastic T-Cell Lymphoma Suggest Alternate Sites of T-Cell Development,. Blood, 2011, 118, 3238-3238.	0.6	0
240	Examination of Genetic Aberrations in Chlamydomphila Psittaci negative MALT Lymphomas of the Ocular Adnexa. Blood, 2012, 120, 1569-1569.	0.6	0
241	Germinal Center Kinase Regulates The Proliferation and Survival Of Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 643-643.	0.6	0
242	A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome. Blood, 2019, 134, 5278-5278.	0.6	0
243	Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies. Blood, 2019, 134, 885-885.	0.6	0
244	Lymphoplasmacytic Lymphoma (Including Waldenström Macroglobulinemia). , 0, , 116-121.		0
245	Mantle Cell Lymphoma. , 0, , 122-125.		0
246	Follicular Lymphoma. , 0, , 126-131.		0
247	Marginal Zone B Cell Lymphoma (Including Malt Type). , 0, , 132-134.		0
248	Hairy Cell Leukemia. , 0, , 135-141.		0
249	Diffuse Large B Cell Lymphoma. , 0, , 153-158.		0
250	Burkitt Lymphoma. , 0, , 159-164.		0
251	The Normal Bone Marrow. , 0, , 5-19.		0
252	Cutaneous T Cell Lymphoma. , 0, , 168-169.		0

#	ARTICLE	IF	CITATIONS
253	Peripheral T Cell Lymphomas, Unspecified. , 0, , 170-172.		0
254	Hepatosplenic T Cell Lymphoma. , 0, , 173-174.		0
255	Angioimmunoblastic T Cell Lymphoma. , 0, , 175-177.		0
256	Adult T Cell Lymphoma/Leukemia. , 0, , 178-179.		0
257	Anaplastic Large Cell Lymphoma. , 0, , 180-182.		0
258	Metastatic Disease. , 0, , 190-196.		0
259	Human Immunodeficiency Virus Infection. , 0, , 20-30.		0
260	Anemias and Aplasias. , 0, , 31-40.		0
261	The Myelodysplastic Syndromes. , 0, , 41-47.		0
262	Myeloproliferative Disease. , 0, , 48-69.		0
263	Lymphomas. , 0, , 90-101.		0
264	Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. , 0, , 102-108.		0
265	CD47 expression patterns in thymic epithelial tumors.. Journal of Clinical Oncology, 2022, 40, 8586-8586.	0.8	0